Navigation Links
Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
Date:12/20/2007

of CNS drugs or drug candidates. Intra-Cellular Therapies uses this platform in its drug discovery and development efforts of proprietary compounds and also to evaluate in-licensing opportunities.

About ITI-007

ITI-007 is the Company's first-in-class dual 5-HT2A receptor antagonist/dopamine receptor protein phosphorylation modulator (DPPM) for the treatment of schizophrenia. ITI-007 has dual properties; it acts as a post- synaptic antagonist and as a pre-synaptic partial agonist. The combination of ITI-007's high-potency blockade of 5HT2A receptors and unique dopamine receptor activity should allow a personalized approach to patient treatment for schizophrenia by making it possible for the first time, to select a clinical dose capable of saturating 5-HT2A receptors while permitting the "dialing in" of an optimal amount of dopamine receptor modulation by simple dose adjustments using a single drug. The ability to optimize the level of dopamine receptor modulation holds promise for the reduction of psychotic symptoms without incurring high levels of dopamine antagonism that cause motor disturbances and other deleterious side effects. In addition, the wide separation of affinity at 5-HT2A and D2 receptors may allow for administration of the appropriate amount of dopamine modulation for antipsychotic maintenance therapy and the treatment of bipolar disorders.

ITI-007 has a low propensity to interact with receptors that mediate deleterious cardiovascular events, sedation, and rapid and significant weight gain.

ITI-007 currently is being evaluated in several Phase I studies examining safety and tolerability, and 5HT2A and D2 occupancy in normal healthy volunteers at doses that interact with both 5-HT2A and dopamine receptors.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc. (ITI), is a biopharmaceutical company that is developing novel drugs for the treatment of diseases and disorders of the Central Nervous System (C
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs
2. LigoCyte Pharmaceuticals Announces Collaboration With Biogen Idec to Develop Anti-CD103 Therapies
3. ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies
4. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
7. Vital Therapies Announces Presentation of ELAD(R) Artificial Liver Data at American Association for the Study of Liver Diseases 2007 Annual Meeting
8. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
9. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
10. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
11. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , Sept. 1, 2015 Emerus Holdings, ... of emergent, inpatient and diagnostic care in partnership ... signed a definitive agreement to receive a strategic ... Carson), a leading health care investment firm. ... high-quality, patient-centric acute episodic and ambulatory clinical services ...
(Date:9/1/2015)... UT Southwestern Medical Center President Dr. Daniel K. ... Michael C. Burgess , M.D., and Joe ... st Century Cures Act, bipartisan legislation in support ... the United States Senate. UT ... department chairs, center directors, and leading researchers – joined ...
(Date:9/1/2015)... 2015  Edwards Lifesciences Corporation (NYSE: EW ), ... and hemodynamic monitoring, is scheduled to present at the ... Regency Boston in Boston, Massachusetts ... A. Mussallem , Edwards Lifesciences, chief executive officer, is ... company discussion with conference attendees at 10:10 a.m. PDT ...
Breaking Medicine Technology:Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 2Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 2U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 4U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 5
(Date:9/1/2015)... , ... September 01, 2015 , ... ... delivery options, Blue Cross and Blue Shield of Minnesota (Blue Cross) has announced ... , Based in San Francisco, Doctor On Demand provides immediate access to ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... Vending Machine,” is still strongly maintaining her firm’s success in the hair care ... In her upcoming city-to-city tour, Ellis will be providing “Look and learn” live ...
(Date:9/1/2015)... , ... September 01, 2015 ... ... Background Screeners (NAPBS®) has announced that Edge Information Management has been ... the Background Screening Credentialing Council (BSCC). , “Achieving and maintaining this ...
(Date:9/1/2015)... ... September 01, 2015 , ... With former IBMers among its founding members, Inmar ... inception more than 35 years ago. A pilot program begun by the company in ... not just those intent on pursuing careers in these fields. The program is now ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... Royal River ... new study that followed men and women for 19 years and found that, among ... did not take multivitamins. , The report is part of the September 2015 issue ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 2Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 3Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 3Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2
... UPMC Health Plan announced the,launch of a small ... small businesses -- UPMC Health Plan,s Small Business ... with 2 to 99,employees a high- quality, easy-to-implement ... tools, and a,dedicated account manager and customer service ...
... shows no link , THURSDAY, Oct. 18 (HealthDay News) -- ... or after exercise will not prevent muscle soreness, a new ... each involving from 10 to 30 people. , Nine of ... and the time spent stretching by participants varied from 40 ...
... and,Reported Diluted Earnings per Share Decreased 1% to $0.84. Diluted Earnings ... 2007 First Nine Months Worldwide Net Revenue Increased 10% to $16.6, ... Share, Before Certain Significant Items, Increased 10% ... to ...
... MITI ), a biopharmaceutical company focusing on ... treatment of cancer,inflammatory and autoimmune diseases, announced today ... Product Dossier (IMPD),for the conduct of a phase ... lymphoblastic leukemia (ALL) in Germany. MT103, a BiTE(R) ...
... 2,200-plus healthcare professionals and exhibitors registered for the,first-ever ... CHICAGO, Oct. 17 With studies from ... of students and,adults enrolling in distance education in ... Information and Management Systems Society (HIMSS),will host its ...
... Our ... Telemedicine Product Line, SUN VALLEY, Calif., Oct. 18 ... new,Bluetooth(R) enabled telemedicine products to their line of disease,management solutions for ... "The addition of A & D,s Bluetooth(R) enabled Blood Pressure ...
Cached Medicine News:Health News:UPMC Health Plan Launches New Product for Small Businesses 2Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 2Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 3Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 4Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 5Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 6Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 7Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 8Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 9Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 10Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 11Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 12Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 13Health News:Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia 2Health News:Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia 3Health News:Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia 4Health News:Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia 5Health News:HIMSS' Second Virtual Conference & Expo Less Than a Month Away 2Health News:HIMSS' Second Virtual Conference & Expo Less Than a Month Away 3Health News:HIMSS' Second Virtual Conference & Expo Less Than a Month Away 4Health News:XTend Medical (XDMC) Adds New Bluetooth(R) Telemedicine Products From A&D Medical 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: